Press release
Sri Lanka Extends Barcode/QR Code Implementation Deadline for Pharmaceutical Labeling
Colombo, Sri Lanka - The National Medicines Regulatory Authority (NMRA) of Sri Lanka has announced an extension to the implementation deadline for barcode or QR code requirements on pharmaceutical product labeling. Originally set for October 1, 2024, the new deadline is now May 31, 2025. This extension aims to provide pharmaceutical manufacturers and distributors with additional time to ensure full compliance with the updated labeling regulations designed to enhance protection against falsified medicines.The initial requirement for affixing stickers on pharmaceutical product packaging remains effective from October 1, 2024. However, the NMRA recognizes the complexities associated with implementing barcode and QR code systems, particularly concerning the necessary infrastructure and data integration. The extended deadline allows stakeholders to thoroughly prepare and implement robust solutions that meet the regulatory standards.
The NMRA's regulations mandate that the barcode or QR code on secondary packaging (cartons) must contain critical product information, including the product name, generic name and strength, batch number, manufacturing and expiry dates, price, and manufacturer's name and address. This initiative is part of a broader effort to strengthen the pharmaceutical supply chain and safeguard public health by improving product traceability and authentication.
Pharmaceutical companies are advised to utilize the extended period to:
1. Upgrade their labeling and packaging systems.
2. Ensure accurate data encoding in QR codes, adhering to the specified data contents.
3. Establish data exchange protocols, if necessary, to comply with potential future reporting requirements.
4. Prepare for the mandatory registration of export shipments in the NMRA's data repository.
The NMRA will continue to provide guidance and support to stakeholders throughout the implementation process to ensure a smooth transition and maintain the integrity of the pharmaceutical market in Sri Lanka.
ST 101, One 42, B/H Ashok Vatika, Near Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad 380 054, Gujarat, India.
Since its inception, Kevision has been on a mission to develop software and systems to protect the authenticity of medicines and other products. In its first year, Kevision launched three modern technologies to provide Serialization and Camera-based inspection systems.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sri Lanka Extends Barcode/QR Code Implementation Deadline for Pharmaceutical Labeling here
News-ID: 3933014 • Views: …
More Releases from Kevision Systems

Updated Sri Lanka Regulatory Guidelines 21 August 2025.
Kevision Systems, a leading provider of track and trace and vision inspection solutions for the pharmaceutical and agrochemical industries, is alerting pharmaceutical manufacturers and exporters to significant updates in Sri Lanka's regulatory guidelines for medicine labeling. The changes, issued by the National Medicines Regulatory Authority (NMRA), aim to enhance protection against falsified products and introduce new standards for secondary packaging.
Key updates include a revised compliance date of December 2025 for…

Italy Extends Pharmaceutical Packaging Compliance Deadline to 2027: How Kevision …
The Italian Medicines Agency (AIFA) has officially extended the compliance deadline for pharmaceutical packaging regulations from 9 February 2025 to 16 February 2027. This decision provides pharmaceutical manufacturers additional time to align with GS1 serialization and aggregation standards while enhancing drug traceability and patient safety.
Understanding the AIFA Regulation Extension
The regulatory framework issued by AIFA aligns Italy's pharmaceutical packaging with the EU Falsified Medicines Directive (FMD). The deadline extension to 2027…

Italy AIFA's New Guidelines for Pharmaceutical Packaging: Powered by Kevision's …
The Italian Medicines Agency (AIFA) has recently issued a draft decree outlining updated regulatory guidelines for pharmaceutical packaging, aimed at aligning with the EU Falsified Medicines Directive (FMD). These changes, effective from 9 February 2025, represent a pivotal step in advancing drug safety, traceability, and compliance within Italy's pharmaceutical industry.
As a trusted leader in Track and Trace solutions, Kevision is committed to helping pharmaceutical manufacturers navigate these new requirements with…

Understanding Beverage Traceability Guidelines in India
In the world of food and beverages, ensuring product safety and quality is more than just a regulatory requirement-it's a commitment to consumers. As the beverage industry continues to grow and evolve, so do the expectations around transparency and traceability. In India, the regulatory landscape for beverage traceability is becoming increasingly robust, driven by a need to safeguard consumer health and maintain trust in the marketplace. This article delves into…
More Releases for NMRA
Updated Sri Lanka Regulatory Guidelines 21 August 2025.
Kevision Systems, a leading provider of track and trace and vision inspection solutions for the pharmaceutical and agrochemical industries, is alerting pharmaceutical manufacturers and exporters to significant updates in Sri Lanka's regulatory guidelines for medicine labeling. The changes, issued by the National Medicines Regulatory Authority (NMRA), aim to enhance protection against falsified products and introduce new standards for secondary packaging.
Key updates include a revised compliance date of December 2025 for…
Major Depressive Disorder Pipeline Outlook Report 2025: Key 75+ Companies and Br …
DelveInsight's "Major Depressive Disorder Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover…
Biotech's Turning Point: 4 Stocks Poised to Ride the 2025 Wave (MDCX, ACTU, CRBU …
Biotech is entering a new phase of growth in summer 2025, backed by scientific momentum, clinical progress, and a more favorable investment landscape. Following a challenging few years, the sector is rebounding as interest rates ease and investors return to innovative, high-conviction names with late-stage programs and differentiated platforms.
New technologies are accelerating timelines across the board. AI is helping to identify drug targets and biomarkers with greater precision. Machine learning…
Investigation announced for Long-Term Investors in shares of Neumora Therapeutic …
An investigation was announced over potential breaches of fiduciary duties by certain directors and officers of Neumora Therapeutics, Inc.
Investors who are current long term investors in Neumora Therapeutics, Inc. (NASDAQ: NMRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NMRA stocks follows a lawsuit filed against Neumora Therapeutics,…
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on …
A deadline is coming up on April 7, 2025 in the lawsuit filed for certain investors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) over alleged securities laws violations by Neumora Therapeutics, Inc.
Investors who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and there are strict and short deadlines running. Deadline: April 7, 2025. NASDAQ: NMRA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Lawsuit filed for Investors in shares of Neumora Therapeutics, Inc. (NASDAQ: NMR …
An investor, who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA), filed a lawsuitover alleged violations of Federal Securities Laws by Neumora Therapeutics, Inc. in connection with certain allegedly false and misleading statements made in connection with Neumora's September 2023 initial public offering (the "IPO").
Investors who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 7,…